Id: acc2421
Group: 2sens
Protein: CYLD
Gene Symbol: CYLD
Protein Id: Q9NQC7
Protein Name: CYLD_HUMAN
PTM: phosphorylation
Site: Ser418
Site Sequence: SLTTENRFHSLPFSLTKMPNT
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: Adult T-cell leukemia/lymphoma
Disease Cellline: MT4
Disease Info:
Drug: MRT67307
Drug Info: "MRT67307 is a dual inhibitor of IKKepsilon and TBK-1 with IC50 values of 160 nM and 19 nM, respectively, in vitro (at 0.1 mM ATP), and also effectively inhibits ULK1 and ULK2 with IC50 values of 45 nM and 38 nM."
Effect: modulate
Effect Info: SMAC mimetics or IKK inhibitors can also disrupt the phosphorylation of CYLD and induce the death of ATLL cells by reducing the CYLD-dependent ubiquitination of RIPK1.
Note:
Score: 4.0
Pubmed(PMID): 32024820
Sentence Index:
Sentence:

Sequence & Structure:

MSSGLWSQEKVTSPYWEERIFYLLLQECSVTDKQTQKLLKVPKGSIGQYIQDRSVGHSRIPSAKGKKNQIGLKILEQPHAVLFVDEKDVVEINEKFTELLLAITNCEERFSLFKNRNRLSKGLQIDVGCPVKVQLRSGEEKFPGVVRFRGPLLAERTVSGIFFGVELLEEGRGQGFTDGVYQGKQLFQCDEDCGVFVALDKLELIEDDDTALESDYAGPGDTMQVELPPLEINSRVSLKVGETIESGTVIFCDVLPGKESLGYFVGVDMDNPIGNWDGRFDGVQLCSFACVESTILLHINDIIPALSESVTQERRPPKLAFMSRGVGDKGSSSHNKPKATGSTSDPGNRNRSELFYTLNGSSVDSQPQSKSKNTWYIDEVAEDPAKSLTEISTDFDRSSPPLQPPPVNSLTTENRFHSLPFSLTKMPNTNGSIGHSPLSLSAQSVMEELNTAPVQESPPLAMPPGNSHGLEVGSLAEVKENPPFYGVIRWIGQPPGLNEVLAGLELEDECAGCTDGTFRGTRYFTCALKKALFVKLKSCRPDSRFASLQPVSNQIERCNSLAFGGYLSEVVEENTPPKMEKEGLEIMIGKKKGIQGHYNSCYLDSTLFCLFAFSSVLDTVLLRPKEKNDVEYYSETQELLRTEIVNPLRIYGYVCATKIMKLRKILEKVEAASGFTSEEKDPEEFLNILFHHILRVEPLLKIRSAGQKVQDCYFYQIFMEKNEKVGVPTIQQLLEWSFINSNLKFAEAPSCLIIQMPRFGKDFKLFKKIFPSLELNITDLLEDTPRQCRICGGLAMYECRECYDDPDISAGKIKQFCKTCNTQVHLHPKRLNHKYNPVSLPKDLPDWDWRHGCIPCQNMELFAVLCIETSHYVAFVKYGKDDSAWLFFDSMADRDGGQNGFNIPQVTPCPEVGEYLKMSLEDLHSLDSRRIQGCARRLLCDAYMCMYQSPTMSLYK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CYLD-Ser341
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CYLD-Ser358
Cancer Intensity
BRCA
COAD 0.411
HGSC
ccRCC 0.723
GBM
HNSC
LUAD 0.346
LUSC
non_ccRCC
PDAC
UCEC -1.48
CYLD-Ser359
Cancer Intensity
BRCA 1.125
COAD 0.923
HGSC -0.341
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC -1.246
PDAC
UCEC -0.461
CYLD-Ser362
Cancer Intensity
BRCA
COAD
HGSC -1.475
ccRCC 0.331
GBM
HNSC 1.296
LUAD 0.031
LUSC
non_ccRCC
PDAC
UCEC -0.182
CYLD-Ser366
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -1.414
LUSC 0.122
non_ccRCC 0.921
PDAC
UCEC 0.371
CYLD-Ser384
Cancer Intensity
BRCA 0.032
COAD
HGSC -2.649
ccRCC -0.097
GBM -0.127
HNSC 0.762
LUAD 0.627
LUSC 0.72
non_ccRCC 0.479
PDAC 0.447
UCEC -0.192
CYLD-Ser395
Cancer Intensity
BRCA
COAD 0.333
HGSC -1.124
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.791
CYLD-Ser396
Cancer Intensity
BRCA -0.611
COAD 0.666
HGSC -1.356
ccRCC 0.15
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 1.15
CYLD-Ser406
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
CYLD-Ser415
Cancer Intensity
BRCA -1.406
COAD -0.166
HGSC 2.624
ccRCC -0.197
GBM -0.067
HNSC -0.794
LUAD 0.011
LUSC 0.201
non_ccRCC 0.333
PDAC -0.536
UCEC -0.003
CYLD-Ser419
Cancer Intensity
BRCA -0.105
COAD -0.524
HGSC -0.476
ccRCC 0.041
GBM 0.594
HNSC -1.261
LUAD 0.144
LUSC -0.15
non_ccRCC 2.656
PDAC -0.353
UCEC -0.566
CYLD-Ser544
Cancer Intensity
BRCA -0.225
COAD
HGSC 0.077
ccRCC 0.157
GBM 1.198
HNSC -0.114
LUAD -1.699
LUSC -0.391
non_ccRCC 1.969
PDAC -0.692
UCEC -0.28
CYLD-Ser549
Cancer Intensity
BRCA -0.4
COAD -0.164
HGSC 0.399
ccRCC -0.005
GBM -1.67
HNSC 1.342
LUAD -0.55
LUSC -1.005
non_ccRCC 1.098
PDAC 1.499
UCEC -0.544
CYLD-Ser557
Cancer Intensity
BRCA 0.69
COAD 0.328
HGSC -2.601
ccRCC -0.234
GBM -0.781
HNSC 0.182
LUAD 0.366
LUSC 0.843
non_ccRCC 0.784
PDAC 0.661
UCEC -0.238
CYLD-Ser565
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.151
GBM -1.411
HNSC 0.32
LUAD 0.94
LUSC
non_ccRCC
PDAC
UCEC
CYLD-Ser836
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CYLD-Tyr15
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CYLD-Tyr563
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.165
GBM
HNSC -0.908
LUAD 1.072
LUSC
non_ccRCC
PDAC
UCEC
CYLD-Tyr832
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: